In the context of prostate cancer, given the interplay of t-CDKs and AR in regulating the transcriptional output of genes involved in cell proliferation and survival, combining t-CDKs inhibitors with hormone therapies is a rational approach that has been shown to augment anti-cancer activity in preclinical studies [84,97,96,163]. This evidence concerns the gene AR and prostate cancer.